Lafunomyl

Alfuzosin Hydrochloride, the active ingredient in Lafunomyl, is an alpha‑1 adrenergic blocker presented as a tablet for oral use. It is prescribed to men with benign prostatic hyperplasia to improve urinary flow and reduce related symptoms. It is marketed in the European Union and is available only by prescription.

GNH USA supplies Lafunomyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets. The company ensures consistent batch release and supports pharmacovigilance activities.

Lafunomyl (alfuzosin) is employed in the therapeutic management of benign prostatic hyperplasia, a condition characterized by non‑cancerous enlargement of the prostate gland that leads to lower urinary tract symptoms in adult men. - Benign prostatic hyperplasia (BPH): improves urinary flow and reduces symptoms such as hesitancy, weak stream, and nocturia. - Urinary retention secondary to BPH: helps to prevent acute urinary retention by relaxing prostatic smooth muscle. - Bladder outlet obstruction due to BPH: reduces obstruction and improves bladder emptying.

Alfuzosin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nasal congestion - Fatigue

Serious or Rare Side Effects: - Orthostatic hypotension - Priapism - Severe allergic reaction (anaphylaxis)

When prescribing or dispensing Lafunomyl, several precautions should be observed to ensure patient safety. - Assess cardiovascular status: evaluate for history of hypotension or syncope before initiating therapy. - Review concomitant medications: avoid use with potent CYP3A4 inhibitors that may increase alfuzosin exposure. - Monitor renal and hepatic function: dose adjustment may be needed in severe impairment. - Caution in elderly patients: increased susceptibility to dizziness and falls. - Avoid abrupt discontinuation: taper if long‑term therapy is stopped to reduce symptom rebound. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Alfuzosin can interact with other medicines, altering its plasma concentration or enhancing pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise alfuzosin levels and increase risk of hypotension. - Concomitant use with other α‑blockers (e.g., tamsulosin, doxazosin): can cause additive blood pressure lowering. - Nitrates: combined use may lead to severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce alfuzosin effectiveness. - Antihypertensive agents (e.g., ACE inhibitors, diuretics): monitor blood pressure for additive effects. - Digoxin: may require monitoring of serum levels due to potential interaction.